Antimicrobial susceptibility of Shiga toxin producing E coli (STEC) strains isolated from human infections and food;Perfil de susceptibilidad a los antimicrobianos en cepas de E coli productoras de Shiga toxina (STEC) aisladas de infecciones humanas y de alimentos

Revista Medica de Chile

Volumn 132, Issue 10, 2004, Pages 1211-1216

  Reyes, Marcelo ^a   Claudia Duran T ^a   Valeria Prado, J ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Escherichia coli O157; Hemolytic uremic syndrome; Shiga toxin

Indexed keywords

AGAR; AMIKACIN; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; SHIGA TOXIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DIARRHEA; DILUTION; ESCHERICHIA COLI; FOOD POISONING; HEMOLYTIC UREMIC SYNDROME; MEAT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MEAT PRODUCTS; SHIGA TOXINS;

EID: 12544259229     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. LÓPEZ E, PRADO V, O'RYAN M, CONTRINI M. Shigella and Shiga toxin producing Escherichia coli causing bloody diarrhea in Latin America. Inf Dis Clin of North Am 2000; 14: 41-65.
2. BESSER RE. Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: An emerging infectious disease. Annu Rev Med 1999; 50: 355-67.
3. RILEY L, REMIS S, HELGERSON SD. Hemorrhagic colitis associated with rare Escherichia coli serotype. N Engl J Med 1983; 308: 681-5.
4. KARMALI MA. Infection by Verocytotoxin producing Escherichia coli. Clin Microbiol Rev 1989; 2: 15-38.
5. GRIFFIN PM, TAUXE RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E coli, and the associated hemolytic uremic syndrome. Epidemiol Rev 1991; 13: 60-98.
6. SIEGLER RL. The hemolytic uremic syndrome. Ped Nephrol 1995; 42: 1505-29.
7. NATARO JP, KAPER JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11: 142-201.
8. LÓPEZ EL, DEVOTO S, FAYAD A, CANEPA C, MORROW AL, CLEARY TG. Association between severity of gastrointestinal prodrome and long term prognosis in classic hemolytic uremic syndrome. J Pediatr 1992; 120: 210-5.
9. PICKERING L, OBRIG T, STAPLETON B. Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coli. J Pediat Infect Dis 1994; 13: 459-76.
10. VIZCAYA MC, SANDOVAL C, SALIN MP, PRADO V. Impacto del síndrome hemolítico urémico en las distintas áreas de salud de la región metropolitana. Rev Chil Infect 1996; 13: 223-30.
11. SAFDAR N, SAID A, GANGNOG R, MAKI D. Risk of hemolytic uremic syndrome after antibiotics treatment of Escherichia coli O157:H7 enteritis. JAMA 2002; 288: 996-1001.
12. WALTERSPEIL J, ASHKENAZI S, MORROW A, CLEARY TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga like toxin 1. Infection 1992; 20: 25-9.
13. PATRICK TK, COLIN RH, BARER M. Induction of type 2 Shiga toxin synthesis in Escherich id coli O157 by 4-quinolones. Lancet 1999; 353: 1588-99.
14. IKEDA K, IDA O, KIMOTO K, TAKATORIAGE T, NAKANISHI N, TATARA K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357-62.
15. SHIOMI M, TOGAWA M, FUJITA K, MURATA R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Peditr Int 1999; 41: 228-32.
16. SCHROEDER CM, ZHAO C. Antimicrobial resistance of Escherichia coli O157 isolated from human, cattle, swine and food. App Environ Microbiol 2002; 68: 576-81.
17. VAN DEN BOGAARD AE, STOBBERING EE. Antibiotic usage in animals: impact on bacterial resistance and public health. Drugs 1999; 58: 589-607.
18. VIDAL M, CARREÑO M, VIDAL R, ARELLANO C, SOLARI V, PRADO V. Evaluación de técnicas moleculares e inmunoenzimáticas para la detección de E coli enterohemorrágica en brotes de toxi-infecciones alimentarias. Rev Méd Chile 2002; 130: 603-9.
19. BASUALDO W, ARBO A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 2003; 22: 374-7.
20. KHAN WA, SEAS C, DHAR U, SALAM MA, BENNISH ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997; 126: 697-703.
21. GORDILLO M, SINGH K, MURRIA B. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1993; 37: 1203-5.
22. FOULDS G, SHEPARD RM, ALLEN RH, FERRAINA RA. Transintestinal elimination of azithromycin in dogs (Abstract 220). In: Proceedings of the Fifth European Congress of Clinical Microbiology and Infectious Diseases, Oslo, 1991.
23. TSUBOI I, HIROHISA I. Antibiotic susceptibility of enterohemorrhagic Escherichia coli O157:H7 isolated from an outbreak in Japan in 1996. Antimicrob Agents Chemother 1998; 42: 431-2.
24. PRADO V, BASUALDO W, ARELLANO C, MARTÍNEZ D, LEVINE MM. Susceptibilidad in vitro de Escherichia coli enterohemorrágica frente a 11 antimicrobianos. Rev Méd Chile 1995; 123: 1085-90.